Hudson worked to shake up research to replace sales from a looming patent cliff for its top-selling drug Dupixent, but his efforts didn’t pay off.
Garijo, one of the pharma world’s few female top executives, spent 15 years at Sanofi, which may help her grasp the company culture better than Hudson, who ruffled some feathers with the French establishment. Yet investors questioned the choice, pointing to Merck’s lackluster performance during ...